Revelation Biosciences, Inc. REVB

Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 TITAN Study. CRO selection advances Phase 2/3 TITAN study execution.

REVB is approaching a critical inflection point that could reshape its operations and market standing. Inflection point signals major strategic or clinical shifts likely to alter company trajectory and investor view.

Revelation Biosciences, Inc. (REVB) holds a $94 billion total addressable market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury per independent market assessment results. Gemini targets a $94 billion market opportunity in acute kidney injury treatment.

Revelation Biosciences, Inc. (REVB) released a corporate update letter to stockholders outlining company progress and strategic initiatives. Corporate update letters detail pipeline advancements and financial strategies that moderately influence investor sentiment and market performance.

Revelation Biosciences, Inc. (REVB) is positioned for a major year ahead with key clinical, regulatory, and partnership milestones expected to drive significant value. Key upcoming milestones in clinical trials, regulatory approvals, and partnerships promise substantial shifts in REVB's market position and performance.

Revelation Biosciences, Inc. (REVB) announced financial results for the three months ended March 31, 2026. Quarterly financial results disclosure affects financial performance and investor sentiment.

Revelation Biosciences, Inc. (REVB) announces formation of an Acute Kidney Injury Advisory Board comprised of key opinion leaders to guide clinical development of its AKI therapeutic candidate. Forming an AKI advisory board advances clinical strategy and credibility but represents a standard milestone without transformative immediate effects.

Revelation Biosciences Inc. (REVB) presented additional positive data from its Prime clinical study. Additional positive clinical data advances REVB's pipeline and could significantly improve investor sentiment and stock performance.

Revelation Biosciences, Inc. (REVB) announced financial results for the three and twelve months ended December 31, 2025. Financial results disclosure affects key financial performance metrics and investor sentiment but is routine without specified major developments.

Revelation Biosciences, Inc. (REVB) has reached an agreement with the FDA regarding its product development, which is expected to streamline the regulatory process for its therapeutic candidates. This collaboration aims to enhance the company's ability to bring innovative solutions to market, potentially improving patient outcomes and expanding its market presence. The agreement signifies a positive step forward in REVB's strategic initiatives and regulatory compliance efforts. The agreement with the FDA is likely to significantly impact REVB's future performance by facilitating product development and regulatory approval.

Revelation Biosciences, Inc. has announced a 1-for-4 reverse stock split effective January 28, 2026. This move is aimed at increasing the per-share price of its common stock, which may help the company meet listing requirements for stock exchanges and improve market perception. The reverse stock split may influence investor sentiment and stock price but is not expected to fundamentally change the company's overall trajectory.

Revelation Biosciences, Inc. has announced the exercise of warrants, resulting in gross proceeds of $11 million. This capital infusion is expected to support the company's ongoing development initiatives and operational activities. The exercise of these warrants reflects investor confidence and positions the company for future growth. The $11 million in gross proceeds is a significant capital boost that can enhance operational capabilities and strategic initiatives.

Revelation Biosciences, Inc. (REVB) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company, potentially impacting its stock performance and investor sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Revelation Biosciences, Inc. has reached an agreement with the FDA regarding the approval pathway for its Gemini product aimed at treating acute kidney injury (AKI). This agreement outlines the necessary steps for regulatory approval, potentially accelerating the development and commercialization of the treatment. The company is optimistic about the implications of this agreement for its future operations and market position. The FDA agreement represents a significant regulatory milestone that could enhance the company's product pipeline and market competitiveness.

Revelation Biosciences, Inc. (REVB) is poised for a promising 2026, driven by advancements in its product pipeline and strategic partnerships. The company is focusing on innovative therapies aimed at addressing significant health challenges, which could enhance its market position. Anticipated regulatory approvals and potential collaborations are expected to bolster investor confidence and financial performance in the coming years. Significant strategic moves and product developments are likely to alter the company's trajectory and investor sentiment.

Revelation Biosciences, Inc. will present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026), highlighting its commitment to advancing research and innovation in critical care nephrology. Participation in a significant conference may enhance visibility and networking opportunities, potentially influencing future developments.

Revelation Biosciences, Inc. has initiated GMP manufacturing of its GEMINI product and a placebo to support later stage clinical development. This step is crucial for advancing the company's clinical trials and potential market introduction of GEMINI, which is aimed at addressing unmet medical needs. Initiating GMP manufacturing is a significant strategic move that could enhance clinical development and investor sentiment.

Revelation Biosciences, Inc. has successfully reached a quorum for its special meeting scheduled on December 3, 2025. This milestone is crucial for the company as it prepares to discuss important matters that could influence its future direction and operations. Reaching a quorum for the special meeting indicates potential strategic discussions that may moderately influence the company's future operations.

Revelation Biosciences, Inc. is preparing for an End-of-Phase 1 meeting with the FDA later this year, which is a significant step in the regulatory process for its product development. This meeting is crucial for discussing the results of their Phase 1 clinical trials and planning the next steps in the development pathway. The upcoming FDA meeting could significantly influence the company's development strategy and investor sentiment.

Revelation Biosciences, Inc. (REVB) is poised to advance its innovative treatment aimed at addressing significant health challenges. The company has made substantial progress in its research and development efforts, positioning itself to potentially transform patient care. With promising results from recent studies, REVB is preparing for the next stages of clinical trials, which could lead to regulatory approvals and market entry. This advancement reflects the company's commitment to pioneering solutions in the healthcare sector. The upcoming clinical trials and potential regulatory approvals could significantly alter the company's trajectory and investor sentiment.

Revelation Biosciences, Inc. reported its financial results for the three and nine months ending September 30, 2025. The company highlighted key metrics, including revenue figures and operational developments, indicating its current financial health and strategic direction. Investors and stakeholders are provided insights into the company's performance and future outlook. The financial results indicate moderate changes in performance that could influence investor sentiment and operational strategies.

Revelation Biosciences, Inc. has announced the exercise of warrants, resulting in gross proceeds of $9.6 million. This capital infusion is expected to support the company's ongoing development efforts and operational activities. The exercise of warrants provides significant funding that may enhance financial performance and support product development.

Revelation Biosciences, Inc. (REVB) announced a special webcast to present positive top-line clinical data. The webcast aims to provide insights into the results of their recent clinical trials, which are expected to enhance the company's position in the market and inform stakeholders about future developments. Positive clinical data can significantly impact investor sentiment and the company's strategic direction.

Revelation Biosciences, Inc. (REVB) announced a webcast and conference call to discuss the top-line data from its PRIME Phase 1b clinical trial. The event aims to provide insights into the trial's outcomes and their implications for the company's future developments. The discussion of Phase 1b top-line data could significantly influence investor sentiment and the company's strategic direction.

Revelation Biosciences, Inc. (REVB) has announced groundbreaking results from its latest research, indicating potential relief for millions suffering from various conditions. The findings suggest that REVB's innovative approach could lead to significant advancements in treatment options, garnering attention from both the medical community and investors. This development positions the company favorably within the biotech sector, potentially enhancing its market presence and financial outlook. The research results indicate a significant advancement in treatment options, likely impacting the company's trajectory and investor sentiment.

Revelation Biosciences, Inc. announced top-line results from its PRIME Clinical Study, demonstrating significant advancements in its therapeutic approach. The study's outcomes indicate promising efficacy and safety profiles, potentially positioning the company favorably within the competitive landscape of biopharmaceuticals. These results may pave the way for further development and commercialization of its innovative treatments. The positive results from the PRIME Clinical Study could significantly enhance the company's market position and investor sentiment.

Revelation Biosciences, Inc. (REVB) is set to release test results within the current quarter, which could provide insights into the company's ongoing projects and potential advancements in its product pipeline. The upcoming test results could significantly impact the company's strategic direction and investor sentiment.

Revelation Biosciences, Inc. reported its financial results for the three and six months ending June 30, 2025. The company highlighted key metrics, including revenue figures and operational developments, reflecting its ongoing strategies and market positioning. Management provided insights into future plans and expectations, indicating a focus on growth and innovation in their sector. Financial results indicate moderate influence on the company's performance and market sentiment.

Revelation Biosciences, Inc. congratulates its former Chairman of the Board, George Tidmarsh, on his appointment as the Head of the FDA Center for Drug Evaluation and Research. This significant role at the FDA is expected to influence drug evaluation processes and regulatory standards. Tidmarsh's new position at the FDA could lead to regulatory changes that significantly impact the company's operations and market positioning.

Revelation Biosciences, Inc. has completed the dosing of patients in its PRIME Study, which is focused on evaluating the safety and efficacy of its investigational product. This milestone marks a significant step in the clinical development of the treatment, aimed at addressing unmet medical needs. The company is now progressing towards the next phases of the study, which will provide further insights into the product's potential benefits. Completion of patient dosing in a pivotal study is a significant milestone that could influence the company's future performance and market perception.